Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Control-IQ technology version 1.5 allows for a wider range of weight and total daily insulin (TDI) entry, in addition to other changes to enhance performance for users with high basal rates. This study evaluated the safety and performance of the updated Control-IQ system for users with basal rates >3 units/h and high TDI in a multicenter, single arm, prospective study. Methods: Adults with type 1 diabetes (T1D) using continuous subcutaneous insulin infusion (CSII) and at least one basal rate over 3 units/h (N = 34, mean age = 39.9 years, 41.2% female, diabetes duration = 21.8 years) used the t:slim X2 insulin pump with Control-IQ technology version 1.5 for 13 weeks. Primary outcome was safety events (severe hypoglycemia and diabetic ketoacidosis (DKA)). Central laboratory hemoglobin A 1c (HbA 1c ) was measured at system initiation and 13 weeks. Participants continued using glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose transport protein 2 (SGLT-2) inhibitors, or other medications for glycemic control and/or weight loss if on a stable dose. Results: All 34 participants completed the study. Fifteen participants used a basal rate >3 units/h for all 24 hours of the day. Nine participants used >300 units TDI on at least one day during the study. There were no severe hypoglycemia or DKA events. Time in range 70-180 mg/dL was 64.8% over the 13 weeks, with 1.0% time <70 mg/dL. Hemoglobin A 1c decreased from 7.69% at baseline to 6.87% at 13 weeks (−0.82%, P < .001). Conclusions: Control-IQ technology version 1.5, with wider range of weight and TDI input and enhancements for users with high insulin requirements, was safe in individuals with T1D in this study.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial
- Date Crossref
- 05/03/2024
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
HealthPartners International Diabetes Center pays non établi dans la noticeOrganisation à but non lucratif
-
Diabetes & Endocrinology Specialists pays non établi dans la noticeÉtablissement de santé
-
Sansum Diabetes Research Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Rocky Mountain Diabetes and Osteoporosis Center pays non établi dans la noticeÉtablissement de santé
-
Tandem Diabetes Care (United States) pays non établi dans la noticeEntreprise
-
Diabetes & pays non établi dans la noticeInstitution
-
Diabetes & Endocrine Treatment Specialists pays non établi dans la noticeInstitution
-
Barbara Davis Center for Diabetes pays non établi dans la noticeInstitution
-
Rocky Mountain Diabetes Center pays non établi dans la noticeInstitution
International Diabetes Center — HealthPartners, Diabetes & Endocrinology Specialists et Sansum Diabetes Research Institute, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.